cervical%20cancer%20-%20treatment
CERVICAL CANCER - TREATMENT
Patients w/ abnormal Pap smear are referred for colonoscopy to screen for presence of cervical cancer.
Colposcopic exam should include inspection of the transformation zone, definition of the extent of the lesion & biopsy of the most abnormal area for tissue diagnosis.
The earliest stages of cervical carcinoma are generally asymptomatic.
Watery vaginal discharge & postcoital bleeding or intermittent spotting may be present & are usually unrecognized by the patient.

Drug Information

Indication: Unresectable or metastatic melanoma. Advanced non-small cell lung carcinoma (NSCLC) whose tumors express PD-L1...

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Indication: Primary treatment of ovarian cancer in combination w/ platinum agent. Metastatic ovarian or breast cancer, aft...

Indication: In combination w/ fluoropyrimidine-based chemotherapy for metastatic colon or rectum carcinoma. In combination...

Indication: In combination w/ 5-fluorouracil (5-FU) & folinic acid for advanced colorectal cancer in patients w/o prio...

Indication: Advanced stage ovarian cancer of epithelial origin.

Indication: Advanced ovarian carcinoma of epithelial origin.

Indication: Monotherapy or in combination w/ other chemotherapeutic agents for metastatic non-seminomatous germ cell carci...

Indication: Squamous cell carcinoma of skin, head, neck & oesophagus, larynx, penis & uterine cervix, bronchus. Ch...

1  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 14 Dec 2016

The addition of ibandronate to adjuvant hormonal therapy provides no benefit to postmenopausal women with HR-positive breast cancer, according to early results from the phase III TEAM IIB trial (BOOG 2006-4)*.